Dermatologicals
Refine search
Pharmaceutical
Biopharma company Pelthos Therapeutics has acquired the US commercialization rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera and Ferrer Internacional. 7 November 2025
Pharmaceutical
Belgian biopharma company UCB has announced a leadership reshuffle, effective January 1, 2026, as part of a plan to reinforce cross-functional collaboration and sustain growth. 7 November 2025
Biosimilars
South Korea’s Samsung Bioepis. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of Pyzchiva, a biosimilar to J&J’s Stelara (ustekinumab), in Europe. The terms of the agreement remain confidential. 6 November 2025
Biotechnology
Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has announced the pricing of a $75 million underwritten offering. 6 November 2025
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma today announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued Technology Appraisal Guidance (TAG) recommending the reimbursement of Anzupgo (delgocitinib) cream. 5 November 2025
Pharmaceutical
Swiss biopharma Relief Therapeutics today announced positive results from its pivotal bioequivalence clinical study evaluating RLF-OD032, Relief’s innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, for the treatment of phenylketonuria (PKU). 29 October 2025
Pharmaceutical
Italian biotech MimeTech has announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to its investigational drug udonitrectag lysine for the treatment of diabetic foot ulcers (DFU). 29 October 2025
Pharmaceutical
Shares in Swiss pharma giant Novartis closed 4% lower Tuesday after the firm reported its third-quarter 2025 financial results. 29 October 2025
Pharmaceutical
US biopharma company Incyte has announced new data from the Phase IIIb TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). 28 October 2025
Biotechnology
Oncolytic immunotherapies specialist Replimune Group has announced that the US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen. 21 October 2025
Pharmaceutical
USA-based clinical-stage dermatology start-up Veradermics has announced the completion of an oversubscribed $150 million Series C financing. 17 October 2025
Biotechnology
Los Angeles, USA-based biotech Pelage Pharmaceuticals has announced the close of a $120 million Series B financing. 16 October 2025
Pharmaceutical
US healthcare giant Johnson & Johnson has announced its third-quarter financial results and guidance for the rest of 2025. 14 October 2025
Biotechnology
M&A news last week featured Denmark-based Genmab’s plans to expand its portfolio with an up to $8 billion acquisition of Dutch biotech Merus along with its cancer candidate petosemtamab. On the research front, Switzerland’s MoonLake Immunotherapeutics saw its shares plunge 90% on disappointing Phase III trial results for its inflammatory disease candidate sonelokimab, and US biotech giant Amgen released new Phase III data on its cardiovascular drug Repatha. Also of note, US pharma giant Pfizer became the first drugmaker to strike a deal with government to lower medicine prices and join President Donald Trump’s Trump\Rx.gov program. 5 October 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. 1 October 2025
Biotechnology
With US President Donald Trump pushing pharma to put America first and reduce US drug prices, which are much higher than anywhere else in the developed world, domestic and other drugmakers have been attracted to a new scheme to sell their medicines direct to consumers/patients, thus avoiding the substantial margins taken by middlemen. 29 September 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s Tremfya (guselkumab) to treat children six years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis (PsO), who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis (PsA). 29 September 2025
Pharmaceutical
Dutch clinical Contract Research Organization (CRO) Julius Clinical today announced the appointment of Bassem Saleh as its new chief executive (CEO). 29 September 2025
Pharmaceutical
French drugmaker Ipsen has revealed the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. 29 September 2025
Biotechnology
US pharma major Bristol Myers Squibb has announced an expansion of its direct-to-patient offerings, providing eligible US patients with steeply discounted prices for Eliquis (apixaban) and Sotyktu (deucravacitinib). 26 September 2025
Biotechnology
USA-based clinical-stage dermatology start-up Veradermics has announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. 5 February 2026
Biosimilars
Russian drugmaker Binnopharm Group together with China’s Mabwell announced plans to localize the production of a monoclonal antibody (MAb)-based drug for the treatment of asthma and atopic dermatitis in Russia. 4 February 2026
Biotechnology
Belgium’s largest drugmaker UCB today announced three-year data from the BE HEARD trials^ for Bimzelx (bimekizumab) in moderate to severe HS. 4 February 2026
Biotechnology
US clinical-stage biotech Sagimet Biosciences’ shares rose 10% to $6.23 after it announced that China-based partner Ascletis Pharma reported positive top-line results in the open-label Phase III trial evaluating the long-term safety of ASC-40 (denifanstat) tablets in patients with moderate to severe acne. 3 February 2026
Biotechnology
The US Food and Drug Administration (FDA) last week lifted the clinical hold on Intellia Therapeutics’ investigational new drug (IND) for its nexiguran ziclumeran (nex-z) for amyloidosis. The US Centers for Medicare and Medicaid Services (CMS) has released the names of 15 more drugs for a third cycle of Medicare price negotiations. On the deal-making front, Moderna signed a commercialization collaboration with Italy’s Recordati on mRNA-3927, and Japan’s Kyowa Kirin revealed that its partner Amgen has terminated the collaboration on dermatology candidate rocatinlimab. 1 February 2026
Biotechnology
Japanese drugmaker Kyowa Kirin late Friday announced the termination of the current rocatinlimab development and commercialization collaboration with US biotech major Amgen. 31 January 2026
Biotechnology
US biotech major Regeneron has presented its financial results for the fourth quarter and full year 2025. 30 January 2026
Pharmaceutical
French pharma major Sanofi reported strong fourth-quarter and full-year results for 2025 on Thursday. 29 January 2026
Pharmaceutical
Spanish dermatology specialist Almirall has announced that China’s National Medical Products Administration (NMPA) has approved Seysara (sarecycline hydrochloride). 29 January 2026
Biotechnology
US drugmakers Moderna and Merck & Co last week released new data on the former’s intismeran autogene and Merck’s Keytruda in the treatment of melanoma. UK pharma major GSK announced an agreement to acquire RAPT Therapeutics, along with its ozureprubart for $2.2 billion. Johnson & Johnson was the first big pharma to announce fourth quarter 2025 financials and forecast further growth. Also of note, Janux Therapeutics entered a collaboration with Bristol Myers Squibb for its investigational oncology drug JANX007 that could earn the company $850 million. 25 January 2026
Biotechnology
Following the positive COAST 1 results in September 2025, two additional global Phase III studies – SHORE and COAST 2 of amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), today delivered a robust body of evidence that supports amlitelimab’s potential in the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis (AD). 23 January 2026
Pharmaceutical
French drugmaker Ipsen announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen’s termination of the R&D agreement. 22 January 2026
Pharmaceutical
US healthcare giant Johnson & Johnson has announced results for fourth-quarter and full-year 2025. 21 January 2026
Biotechnology
Californian biopharma Corvus Pharmaceuticals has announced positive results from cohort four of the randomized, blinded, placebo-controlled Phase I trial of soquelitinib in moderate to severe atopic dermatitis. 21 January 2026
Biotechnology
USA-based mRNA vaccines company Moderna’s shares were flat in pre-market activity, as the company announced awaited new clinical data on its investigational mRNA-based individualized neoantigen therapy (INT). 20 January 2026
Pharmaceutical
US commercial-stage biopharma Pelthos Therapeutics has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance (Nasdaq: HRZN), with $30 million funded at closing and up to $20 million available if certain milestones are met. 14 January 2026
Biotechnology
Spanish dermatology specialist Almirall is using its appearance at the 44th JP Morgan Healthcare Conference in San Francisco to set out an active 2026 clinical agenda, leaning into proof-of-concept work across immune-driven skin diseases and pushing one bispecific antibody into first-in-human testing. 14 January 2026
Pharmaceutical
Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-interleukin (IL)-15 antibody, TEV-'408. 12 January 2026
Biotechnology
The launch of USA-based Poplar Therapeutics has been announced, alongside a $50 million Series A financing led by SR One, Vida Ventures and Platanus. 8 January 2026
Biotechnology
Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. 7 January 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze